{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:39:25Z","timestamp":1791909565597,"version":"4.3.4"},"reference-count":39,"publisher":"Wiley","issue":"11-12","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The doping control analyses at the XXXII Olympic Games (July 23 to August 8, 2021) and the XVI Paralympic Games (August 24 to September 5, 2021) held in Tokyo, Japan, after a year of delay due to the COVID\u201019 pandemic are summarized in this paper. A new satellite facility at the existing World Anti\u2010Doping Agency (WADA)\u2010accredited Tokyo laboratory was established and fully operated by 278 staff, including 33 Tokyo laboratory staff, 49 international experts, and 196 Japanese temporary staff. The numbers of urine samples were 5081 (Olympics) and 1519 (Paralympics), and the numbers of blood samples were 1103 (Olympics) and 500 (Paralympics). The laboratory could prepare for analysis in advance using a paperless chain\u2010of\u2010custody system, allowing for faster turnaround time reporting. For the first time, a new polymerase chain reaction method for detecting erythropoietin (EPO) gene doping was used. The laboratory also analyzed blood samples for detecting steroid esters following the spotting of collected venous EDTA blood onto dried blood spot cards. Moreover, full\u2010scan data acquisition using high\u2010resolution mass spectrometers was performed for all urine samples, allowing for detecting traces of doping substances, which are not currently analyzed in the subsequent data processing. The presence of some prohibited substances was confirmed, resulting in 8 atypical findings (ATFs) and 11 adverse analytical findings (AAFs), including homologous blood transfusion (2 cases) and recombinant EPO in the blood (1 case), at the Olympics, whereas 2 ATFs and 10 AAFs were reported at the Paralympics.<\/jats:p>","DOI":"10.1002\/dta.3381","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T04:43:34Z","timestamp":1665204214000},"page":"1836-1852","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Doping control analyses during the Tokyo 2020 Olympic and Paralympic Games"],"prefix":"10.1002","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3614-4121","authenticated-orcid":false,"given":"Masato","family":"Okano","sequence":"first","affiliation":[{"name":"Anti\u2010Doping Laboratory LSI Medience Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Ikekita","sequence":"additional","affiliation":[{"name":"Anti\u2010Doping Laboratory LSI Medience Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiko","family":"Sato","sequence":"additional","affiliation":[{"name":"Anti\u2010Doping Laboratory LSI Medience Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Anti\u2010Doping Laboratory LSI Medience Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Kageyama","sequence":"additional","affiliation":[{"name":"Anti\u2010Doping Laboratory LSI Medience Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Anti\u2010Doping Laboratory LSI Medience Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arisa","family":"Aoi","sequence":"additional","affiliation":[{"name":"Anti\u2010Doping Laboratory LSI Medience Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asami","family":"Miyamoto","sequence":"additional","affiliation":[{"name":"Anti\u2010Doping Laboratory LSI Medience Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Momobayashi","sequence":"additional","affiliation":[{"name":"Anti\u2010Doping Laboratory LSI Medience Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Ota","sequence":"additional","affiliation":[{"name":"Anti\u2010Doping Laboratory LSI Medience Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Ishige","sequence":"additional","affiliation":[{"name":"Anti\u2010Doping Laboratory LSI Medience Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Sakurai","sequence":"additional","affiliation":[{"name":"Anti\u2010Doping Laboratory LSI Medience Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Shiomura","sequence":"additional","affiliation":[{"name":"Anti\u2010Doping Laboratory LSI Medience Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuha","family":"Takemine","sequence":"additional","affiliation":[{"name":"Anti\u2010Doping Laboratory LSI Medience Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuma","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Anti\u2010Doping Laboratory LSI Medience Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohisa","family":"Hikota","sequence":"additional","affiliation":[{"name":"Anti\u2010Doping Laboratory LSI Medience Corporation  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"World Anti\u2010Doping Agency.The World Anti\u2010Doping Code. International Standard for Laboratories (ISL) 2021 Montreal 2021. Accessed August 20 2022.https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/isl_2021.pdf"},{"key":"e_1_2_6_3_1","unstructured":"International Olympic Committee.The Playbook Workforce Accessed September 20 2022.https:\/\/stillmed.olympics.com\/media\/Documents\/Olympic-Games\/Tokyo-2020\/Playbooks\/The-Playbook-Workforce-V3.pdf"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/jms.4077"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.8119"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11419\u2010015\u20100279\u20104"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00216\u2010015\u20108699\u2010x"},{"key":"e_1_2_6_8_1","unstructured":"World Anti\u2010Doping Agency.Analysis Reporting and management of urinary human chorionic gonadotrophin (hCG) and luteinizing hormone (LH) findings in male athletes. WADA Technical Document \u2013 TD2021CG\/LH Montreal. 2021. Accessed September 10 2022.https:\/\/www.wada-ama.org\/sites\/default\/files\/2022-01\/td2021cg-lh_final_eng_0.pdf"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1394"},{"key":"e_1_2_6_10_1","unstructured":"World Anti\u2010Doping Agency.Analysis measurement and reporting of endogenous anabolic androgenic steroid (EAAS) markers of the urinary steroid profile. WADA Technical Document \u2013 TD2021EAAS Montreal. 2021. Accessed September 10 2022.https:\/\/www.wada-ama.org\/sites\/default\/files\/2022-01\/td2021eaas_final_eng_v_2.0.pdf"},{"key":"e_1_2_6_11_1","unstructured":"World Anti\u2010Doping Agency.Analysis detection of synthetic forms of prohibited substances by GC\/C\/IRMS. WADA Technical Document \u2013 TD2021IRMS Montreal. 2021. Accessed September 10 2022.https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/td2021irms_final_eng_v_2.0.pdf"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2989"},{"key":"e_1_2_6_13_1","unstructured":"World Anti\u2010Doping Agency.Analysis Harmonization of analysis and reporting of erythropoietin (EPO) and other EPO\u2010receptor agonists (ERAs) by polyacrylamide gel electrophoretic (PAGE) analytical methods. WADA Technical Document \u2013 TD2021EPO Montreal.2021. Accessed September 10 2022.https:\/\/www.wada-ama.org\/sites\/default\/files\/2022-01\/td2021epo_final_eng_v_2.0_0.pdf"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2008.04.007"},{"key":"e_1_2_6_15_1","unstructured":"World Anti\u2010Doping Agency.Analysis Human growth hormone (hGH) isoform differential immunoassays for doping control analyses. WADA Technical Document \u2013 TD2021GH Montreal.2021. Accessed September 10 2022.https:\/\/www.wada-ama.org\/sites\/default\/files\/2022-01\/td2021gh_final_eng_0.pdf"},{"key":"e_1_2_6_16_1","unstructured":"World Anti\u2010Doping Agency.Analysis laboratory guidelines. Human growth hormone (hGH) biomarkers test Montreal.2021. Accessed September 10 2022.https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/wada_guidelines_hgh_biomarkers_test_v3_jan_2021_eng.pdf"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2013.208538"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.1868"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymeth.2011.08.009"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2010.49"},{"key":"e_1_2_6_21_1","unstructured":"World Anti\u2010Doping Agency.Laboratory guidelines. Gene doping detection based on polymerase chain reaction (PCR) Montreal.2021. Accessed September 10 2022.https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/wada_guidelines_for_gene_doping_pcr_test_v1_jan_2021_eng.pdf"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1021\/ac034434z"},{"key":"e_1_2_6_23_1","unstructured":"World Anti\u2010Doping Agency.Analytical requirements for the haematological module of the athlete biological passport. WADA Technical Document \u2013 TD2021BAR Montreal.2021. Accessed September 10 2022.https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/td2021bar_final_eng_v2.0.pdf"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2014.03.013"},{"key":"e_1_2_6_25_1","unstructured":"World Anti\u2010Doping Agency.Dried blood spots (DBS) for doping control requirements and procedures for collection transport analytical testing and storage. WADA Technical Document \u2013 TD2021DBS Montreal.2021. Accessed September 10 2022.https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/td2021dbs_final_eng.pdf"},{"key":"e_1_2_6_26_1","unstructured":"World Anti\u2010Doping Agency.Athlete passport management unit requirements and pocedures. WADA Technical Document \u2013 TD2021APMU Montreal.2021. Accessed September 10 2022.https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/td2021apmu_final_eng_0.pdf"},{"key":"e_1_2_6_27_1","unstructured":"World Anti\u2010Doping Agency.Report of the independent observers \u2013 Olympic Games Tokyo 2020 Montreal.2022. Accessed September 10 2022.https:\/\/www.wada-ama.org\/sites\/default\/files\/2022-01\/IO%20Report_2020%20Tokyo%20Olympic%20Games_Final.pdf"},{"key":"e_1_2_6_28_1","unstructured":"World Anti\u2010Doping Agency.Meclofenoxate. WADA Technical Letter \u2013 TL01 Montreal.2021. Accessed September 10 2022.https:\/\/www.wada\u2010ama.org\/sites\/default\/files\/2022\u201001\/tl01_meclofenoxate_v4.0.pdf"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/rcm.9183"},{"key":"e_1_2_6_30_1","unstructured":"World Anti\u2010Doping Agency.Minimum criteria for chromatographic\u2010mass spectrometric confirmation of the identify if analytes for doping control purposes. WADA Technical Document\u2013TD2021IDCR Montreal.2021. Accessed September 10 2022.https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/td2021idcr_final_eng_0.pdf"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2504"},{"key":"e_1_2_6_32_1","unstructured":"World Anti\u2010Doping Agency.Trimetazidine. WADA Technical Letter \u2013 TL13 Montreal.2021. Accessed September 10 2022.https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/tl13_trimetazidine_eng_2021_1.pdf"},{"key":"e_1_2_6_33_1","unstructured":"World Anti\u2010Doping Agency.Minimum reporting level for certain substances known to be potential meat contaminants. WADA Technical Letter \u2013 TL23 Montreal.2021. Accessed September 10 2022.https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/tl23_growth_promoters_eng_2021_0.pdf"},{"key":"e_1_2_6_34_1","unstructured":"World Anti\u2010Doping Agency.Harmonization of analysis and reporting of 19\u2010norsteroids related to nandrolone. WADA Technical Document \u2013 TD2021NA Montreal.2021. Accessed September 10 2022.https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/td2021na_final_eng_v2.0_m.pdf"},{"key":"e_1_2_6_35_1","unstructured":"World Anti\u2010Doping Agency.Ethylmorphine. WADA Technical Letter \u2013 TL22 Montreal.2021. Accessed September 10 2022.https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/tl22_ethylmorphine_eng_2021.pdf"},{"key":"e_1_2_6_36_1","unstructured":"World Anti\u2010Doping Agency.Laboratory documentation packages. WADA Technical Document \u2013 TD2021LDOC Montreal.2021. Accessed September 10 2022.https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/td2021ldoc_final_eng_0.pdf"},{"key":"e_1_2_6_37_1","unstructured":"World Anti\u2010Doping Agency.Minimum required performance levels for detection and identification of non\u2010threshold substances. WADA Technical Document \u2013 TD2019MRPL Montreal.2019. Accessed September 10 2022.https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/td2019mrpl_eng.pdf"},{"key":"e_1_2_6_38_1","unstructured":"World Anti\u2010Doping Agency.Analysis Harmonization of analysis and reporting of erythropoietin (EPO) and other EPO\u2010receptor agonists (ERAs) by polyacrylamide gel electrophoretic (PAGE) analytical methods. WADA Technical Document \u2013 TD2022EPO Montreal.2021. Accessed September 10 2022.https:\/\/www.wada-ama.org\/sites\/default\/files\/2022-01\/td2022epo_v1.0_final_eng_0.pdf"},{"key":"e_1_2_6_39_1","unstructured":"World Anti\u2010Doping Agency.Report of the independent observers\u2014Paralympic Games Tokyo 2020 Montreal.2022. Accessed September 10 2022.https:\/\/www.wada-ama.org\/sites\/default\/files\/2022-08\/io_report_2020_tokyo_paralympic_games_final_0.pdf"},{"key":"e_1_2_6_40_1","unstructured":"World Anti\u2010Doping Agency.The world anti\u2010doping code. The 2022 Prohibited List. International Standard Montreal. 2022. Accessed September 10 2022.https:\/\/www.wada-ama.org\/sites\/default\/files\/2022-01\/2022list_final_en_0.pdf"}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.3381","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/dta.3381","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.3381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T22:34:08Z","timestamp":1760394848000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.3381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":39,"journal-issue":{"issue":"11-12","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1002\/dta.3381"],"URL":"https:\/\/doi.org\/10.1002\/dta.3381","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,18]]},"assertion":[{"value":"2022-09-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}